US OptionsDetailed Quotes
VIR250117C17500
- 0.16
- +0.11+220.00%
15min DelayClose Jan 8 16:00 ET
0.60High0.16Low
0.35Open0.05Pre Close421 Volume41 Open Interest17.50Strike Price14.03KTurnover173.64%IV41.51%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.16Extrinsic Value100Contract SizeAmericanOptions Type0.1102Delta0.0604Gamma83.20Leverage Ratio-0.0378Theta0.0003Rho9.17Eff Leverage0.0034Vega
Vir Biotechnology Stock Discussion
Sign in to post a comment
$Vir Biotechnology (VIR.US)$ Dont be fools... operating at a loss and less than 2 bil market cap. Anyone serious could buy them out if they had anything worth owning. Maybe im wrong...
2
2
3
$Vir Biotechnology (VIR.US)$ bought in too high.. have to hold it.. potential stock for future.
1
1
$Vir Biotechnology (VIR.US)$
Congratulations to trader who have bought it on premarket for day trade profit.
Market is going downtrend for the incoming fed announcement. Lock on profit today as tomorrow market will be closed.
Today good opportunity to swing trade $ $Sana Biotechnology (SANA.US)$ $Absci Corp (ABSI.US)$
Pick the right momentum stock to trade for profit.
Follow me, follow momentum
Congratulations to trader who have bought it on premarket for day trade profit.
Market is going downtrend for the incoming fed announcement. Lock on profit today as tomorrow market will be closed.
Today good opportunity to swing trade $ $Sana Biotechnology (SANA.US)$ $Absci Corp (ABSI.US)$
Pick the right momentum stock to trade for profit.
Follow me, follow momentum
$Palantir (PLTR.US)$ nice cash grab. keep on holdin guys lol. $Vir Biotechnology (VIR.US)$ to the moon see u at 20
5
2
1
$Vir Biotechnology (VIR.US)$ Benzinga· 1 min ago
Vir Biotechnology Is Presenting Initial Phase 1 Data From Two Of Its Dual-masked T-cell Engagers (TCEs): VIR-5818, Targeting A Variety Of HER2-expressing Solid Tumors; And VIR-5500, Targeting PSMA In Metastatic Castration-resistant Prostate Cancer
Vir Biotechnology Inc - Vir-5818 Shows 50% Tumor Shrinkage in Her2 Cancers at ≥400 ΜG/Kg
Vir Biotechnology Is Presenting Initial Phase 1 Data From Two Of Its Dual-masked T-cell Engagers (TCEs): VIR-5818, Targeting A Variety Of HER2-expressing Solid Tumors; And VIR-5500, Targeting PSMA In Metastatic Castration-resistant Prostate Cancer
Vir Biotechnology Inc - Vir-5818 Shows 50% Tumor Shrinkage in Her2 Cancers at ≥400 ΜG/Kg
2
No comment yet
QMengColdJoke : After vigorously spending VIR still has 1 billion NET cash. Just say before this jump, This company’s science is literally prices at book value, and science is free… Any buy out is robbery.
Lucky1688 QMengColdJoke : Is this good news or bad news? Little White seeks guidance.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")